Similar articles

• Induction chemotherapy for acute myelogenous leukemia.

  Kalaycio M. Kalaycio M. Curr Hematol Rep. 2005 Jan;4(1):49-50. Curr Hematol Rep. 2005. PMID: 15610659 Clinical Trial. No abstract available.
• Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients.

  Kröger N, Damon L, Zander AR, Wandt H, Derigs G, Ferrante P, Demirer T, Rosti G; Solid Tumor Working Party of the European Group for Blood and Marrow Transplantation; German Adjuvant Breast Cancer Study Group; University of California, San Francisco. Kröger N, et al. Bone Marrow Transplant. 2003 Dec;32(12):1153-7. doi: 10.1038/sj.bmt.1704291. Bone Marrow Transplant. 2003. PMID: 14647269 Review.
• Therapeutic milestones. Novantrone (mitozantrone).

  Cotter FE. Cotter FE. Br J Clin Pract. 1988 May;42(5):207-9. Br J Clin Pract. 1988. PMID: 3063315 Review. No abstract available.
• Probable cures of adult acute leukemia using short term intensive investigational chemotherapy.

  Vaughan WP, Karp JE, Burke PJ. Vaughan WP, et al. Nebr Med J. 1984 Aug;69(8):264-8. Nebr Med J. 1984. PMID: 6483053 No abstract available.
• Mitoxantrone in the treatment of refractory and relapsed non-lymphoblastic acute leukaemia.

  Pretnar J. Pretnar J. Bone Marrow Transplant. 1989 Dec;4 Suppl 3:59-60. Bone Marrow Transplant. 1989. PMID: 2697403 Review. No abstract available.